By expenditures
| Name | Title | Type |
|---|---|---|
| Roselle Togonon | Comptroller | Auditee |
| Rizalito Paglingayen | Chief Financial Officer | Auditee |
| No contacts on file | ||
| ID | Year | Date Accepted | Auditor | Spend |
|---|---|---|---|---|
| 361393 | 2023 | 2025-07-02 | Ernst & Young | $19.15M |
| 306394 | 2022 | 2024-05-15 | Ernst and Young LLP | $24.34M |
| Audit | Year | Accepted | Finding | Ref | Severity | Repeat | Requirement |
|---|---|---|---|---|---|---|---|
| 361393 | 2023 | 2025-07-02 | 1146879 | 2023-009 | Significant Deficiency | - | I |
| 361393 | 2023 | 2025-07-02 | 1146878 | 2023-009 | Significant Deficiency | - | I |
| 361393 | 2023 | 2025-07-02 | 1146877 | 2023-009 | Significant Deficiency | - | I |
| 361393 | 2023 | 2025-07-02 | 1146876 | 2023-009 | Significant Deficiency | - | I |
| 361393 | 2023 | 2025-07-02 | 1146875 | 2023-009 | Significant Deficiency | - | I |
| 361393 | 2023 | 2025-07-02 | 1146874 | 2023-008 | Material Weakness | - | N |
| 361393 | 2023 | 2025-07-02 | 1146873 | 2023-007 | Material Weakness | - | N |
| 361393 | 2023 | 2025-07-02 | 1146872 | 2023-006 | Material Weakness | - | N |
| 361393 | 2023 | 2025-07-02 | 1146871 | 2023-005 | Significant Deficiency | - | N |
| 361393 | 2023 | 2025-07-02 | 1146870 | 2023-004 | Significant Deficiency | - | L |
| 361393 | 2023 | 2025-07-02 | 570437 | 2023-009 | Significant Deficiency | - | I |
| 361393 | 2023 | 2025-07-02 | 570436 | 2023-009 | Significant Deficiency | - | I |
| 361393 | 2023 | 2025-07-02 | 570435 | 2023-009 | Significant Deficiency | - | I |
| 361393 | 2023 | 2025-07-02 | 570434 | 2023-009 | Significant Deficiency | - | I |
| 361393 | 2023 | 2025-07-02 | 570433 | 2023-009 | Significant Deficiency | - | I |
| 361393 | 2023 | 2025-07-02 | 570432 | 2023-008 | Material Weakness | - | N |
| 361393 | 2023 | 2025-07-02 | 570431 | 2023-007 | Material Weakness | - | N |
| 361393 | 2023 | 2025-07-02 | 570430 | 2023-006 | Material Weakness | - | N |
| 361393 | 2023 | 2025-07-02 | 570429 | 2023-005 | Significant Deficiency | - | N |
| 361393 | 2023 | 2025-07-02 | 570428 | 2023-004 | Significant Deficiency | - | L |
| 306394 | 2022 | 2024-05-15 | 973435 | 2022-007 | Significant Deficiency | - | I |
| 306394 | 2022 | 2024-05-15 | 973434 | 2022-007 | Significant Deficiency | - | I |
| 306394 | 2022 | 2024-05-15 | 973433 | 2022-007 | Significant Deficiency | - | I |
| 306394 | 2022 | 2024-05-15 | 973432 | 2022-006 | Material Weakness | - | B |
| 306394 | 2022 | 2024-05-15 | 973431 | 2022-006 | Material Weakness | - | B |
| 306394 | 2022 | 2024-05-15 | 973430 | 2022-006 | Material Weakness | - | B |
| 306394 | 2022 | 2024-05-15 | 396993 | 2022-007 | Significant Deficiency | - | I |
| 306394 | 2022 | 2024-05-15 | 396992 | 2022-007 | Significant Deficiency | - | I |
| 306394 | 2022 | 2024-05-15 | 396991 | 2022-007 | Significant Deficiency | - | I |
| 306394 | 2022 | 2024-05-15 | 396990 | 2022-006 | Material Weakness | - | B |
| 306394 | 2022 | 2024-05-15 | 396989 | 2022-006 | Material Weakness | - | B |
| 306394 | 2022 | 2024-05-15 | 396988 | 2022-006 | Material Weakness | - | B |